HCW Biologics Inc. (HCWB)
| Market Cap | 2.46M -70.6% |
| Revenue (ttm) | 6.72M +707.0% |
| Net Income | -21.41M |
| EPS | -27.18 |
| Shares Out | 2.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,172 |
| Open | 1.160 |
| Previous Close | 1.180 |
| Day's Range | 1.100 - 1.189 |
| 52-Week Range | 1.090 - 23.940 |
| Beta | 2.42 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a... [Read more]
Financial Performance
In 2025, HCW Biologics's revenue was $54,232, a decrease of -97.89% compared to the previous year's $2.57 million. Losses were -$22.30 million, -25.73% less than in 2024.
Financial StatementsNews
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer
HCW Biologics registers to sell 1.81M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.81M shares of common stock. The company is not selling any…
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on October 2, 2026, providing details about a securities offering with the SEC.
HCW Biologics Proxy statement: Proxy filing
HCW Biologics filed a proxy statement on October 1, 2026, providing details for shareholder voting and corporate governance matters.
HCW Biologics prices 903,614 units at $1.6599 in private placement
HCW Biologics (HCWB) announced the pricing of its $1.5M private placement with an existing stockholder of the company. The company agreed to issue and sell an aggregate of 903,614 units.
HCW Biologics Announces Pricing of $1.5 Million Private Placement
MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion imm...
HCW Biologics Proxy statement: Proxy filing
HCW Biologics filed a proxy statement on September 9, 2026, providing details for shareholder voting and corporate governance matters.
HCW Biologics enters exclusive HCW11-006 distribution pact with Akron Biotech
HCW Biologics (HCWB) announced that the company has entered into an exclusive distribution agreement with Akron Biotech for the commercialization of HCW11-006 for use as a reagent to support a…
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent
HCW Biologics Proxy statement: Proxy filing
HCW Biologics filed a proxy statement on September 8, 2026, providing details for shareholder voting and corporate governance matters.
HCW Biologics receives patent allowance for alopecia areata drug
HCW Biologics (HCWB) announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to use of HCW9302 to treat alopecia areata. Together with…
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatme...
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of it...
HCW Biologics files to sell 1.24M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.24M shares of common stock. The company is not selling any…
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.
HCW Biologics Earnings release: Q2 2026
HCW Biologics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
HCW Biologics Quarterly report: Q2 2026
HCW Biologics has published its Q2 2026 quarterly earnings report on August 14, 2026.
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative f...
HCW Biologics announces pricing of $1.6M private placement
HCW Biologics (HCWB) announced the pricing of its $1.6M private placement offering with a group of investors, including officers, directors and an existing stockholder of the company. Pursuant to a…
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immu...
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
Company requested Type B pre-IND meeting with U.S. FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b HCW11-018b has demonstrated potenti...
HCW Biologics regains compliance with Nasdaq
HCW Biologics (HCWB) reported that the Nasdaq Hearings Panel of Nasdaq found that the company regained compliance with Listing Rule 5550, the “Bid Price Rule,” per the terms set forth…
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative f...
Hcw Biologics Inc trading halted, news pending
19:50 EDT Hcw Biologics (HCWB) Inc trading halted, news pending